You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023414029
Dec 202386013
Jan 2024147015
Feb 2024176020
Mar 2024174026
Apr 2024137013
May 202410804
Jun 20248403
Jul 202474015
Aug 20247407
Sep 20245803
Oct 202492010
Nov 202413407
Dec 20248906
Jan 202586015
Feb 202530018
Mar 20250019
Apr 2025106
May 2025008
Jun 2025005
Total19640242